Neutrophils from Brazilian patients with Graves' disease: Some biochemical and functional aspects

Cell Biochemistry and Function

Volumn 23, Issue 5, 2005, Pages 297-306

  Russo Carbolante, E M S ^a   Polizzelo, A C M ^a   Azzolini, A E C S ^a   Maciel, L M Z ^a   Lucisano Valim, Yara Maria ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antioxidant defences; Chemiluminescence; Flow cytometry; Neutrophil receptors; Oxygen reactive species

Indexed keywords

ANTITHYROID AGENT; COMPLEMENT RECEPTOR; FC RECEPTOR; GLUTATHIONE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN RECEPTOR; LUMINOL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; ARTICLE; BRAZIL; CHEMICAL ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; EUTHYROIDISM; EYE DISEASE; FLUORESCENCE; GRAVES DISEASE; HUMAN; HUMAN CELL; HYPERTHYROIDISM; INFLAMMATION; MYXEDEMA; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY BURST; TISSUE INJURY;

ANTIGEN-ANTIBODY COMPLEX; BRAZIL; CASE-CONTROL STUDIES; CHEMILUMINESCENT MEASUREMENTS; COMPLEMENT SYSTEM PROTEINS; GLUTATHIONE; GRAVES DISEASE; HUMANS; HYDROGEN PEROXIDE; LUMINOL; NEUTROPHILS; RECEPTORS, IGG; RESPIRATORY BURST; SUPEROXIDE DISMUTASE; SUPEROXIDES;

EID: 24944442831     PISSN: 02636484     EISSN: None     Source Type: Journal    
DOI: 10.1002/cbf.1164     Document Type: Article

References (41)

1. Kiljanski J, Nebes V, Stachura I, Kennerdell JS, Wall JR. Should Graves' disease be considered a collagen disorder of the thyroid, skeletal muscle and connective tissue? Horm Metab Res 1995; 27: 528-532.
2. Fatourechi V, Edwards WD. Graves' disease and low-output cardiac dysfunction: implications for autoimune disease in endomyocardial biopsy tissue from eleven patients. Thyroid 2000; 10: 601-605.
3. Maciel LM, Rodriguez SS, Dibbern RS, Navarro PA, Donadi EA. Association of the HLA-DRB1*0301 and HLA-DQA1*0501 alleles with Graves' disease in a population representing the gene contribution from several ethnic backgrounds. Thyroid 2001; 11: 31-35.
4. Hunt PJ, Marshall SE, Weetman AP, et al. Histocompatibility leucocyte antigens and closely linked immunomodulatory genes in autoimmune thyroid disease. Clin Endocrinol 2001; 55: 491-400.
5. Amino N, Hagen SR, Yamada N, Refetoff S. Measurement of circulating thyroid microsomal antibodies by the tanned red cell-hemagglutination technique. Its usefulness in the diagnosis of autoimmune thyroid disease. Clin Endocrinol 1976; 5: 115.
6. Mori T, Kriss JP. Measurements by competitive binding radioassay of serum antimicrosomal and antithyroglobulin antibodies in Graves' disease and other thyroid disorders. J Clin Endocrinol Metab 1971; 33: 688.
7. Kiljanski J, Wall JR. The ocular muscle cell: a target of the immune system in endocrine ophtalmopathy. Int Arch Allergy Immunol 1995; 106: 204-212.
8. Degroot LJ, Quintans J. The causes of autoimmune thyroid disease. Endocr Rev 1989; 10: 537-562.
9. Kubota S, Gunji K, Stolarski C, Kennerdell JS, Wall J. Revaluation of the prevalences of serum autoantibodies reactive with '64-kd eye muscle proteins' in patients with thyroid-associated ophthalmopathy. Thyroid 1998; 8: 175.
10. Antonelli A, Palia R, Casarosa L, Fallahi P, Baschieri L. IgG, IgA and C3 deposits in extra thyroidal manifestations of autoimmune Graves' disease: their in vitro solubilization by intravenous immunoglobulins. Clin Exp Rheumatol 1996; 14(Suppl. 15): 531-535.
11. Fujiwara H, Torisu M, Koitabashi Y, Baba T, Esaki H. Immune complex deposits in thyroid gland of patients with Graves' disease: I. Complement system and thyroid gland of patients with Graves' disease. Clin Immunol Immunopathol 1981; 19: 98-108.
12. Gadd KJ, Keid KB. The binding of complement component C3 to antigen-antibody aggregates after activation of the alternative pathway in human serum. Biochem J 1981; 195: 471-480.
13. Marzocchi-Machado CM, Polizello ACM, Azzolini AECS, Lucisano-Valim YM. The influence of antibody functional affinity on the receptor functions involved in the clearance of circulating immune complexes anti-BSA IgG/BSA. Immunol Invest 1999; 28: 80-101.
14. Metcalf JA, Gallin JI, Nauseef WM, Root RK. Intracellular granule constituents. In Laboratory of Neutrophil Function, Metcalf FA, Gallin FI, Nauseef WM, Root RK (eds). Raven Press: New York, 1986; 116, 117, 167-169.
15. Oppenheimer JH, Schwartz HL, Strait KA. The molecular basis of thyroid hormone action. In The Thyroid. A Fundamental and Clinical Text (7th edn), Braverman LE, Utiger RD, Werner SC, Ingbar SH (eds). JB Lippincott: New York, 1996; 162-184.
16. Kurland GS, Krotkov MV, Freedberg AS. Oxygen consumption and thyroxine deiodination by human leucocytes. J Clin Endocrinol Met 1960; 20: 35-46.
17. Sbarra AJ, Karnovsky ML. The biochemical basis of phagocytosis: I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. J Biol Chem 1959; 234: 1355-1362.
18. Chiovato L, Bassi P, Santini F, et al. Antibodies producing complement-mediated thyroid cytotoxicity in patients with atrophie or goitrous autoimmune thyroiditis. J Clin Endocr Metab 1993; 77: 1700-1705.
19. Weetman AP, Cohen SB, Oleesky DA, Morgan BP. Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease. Clin Exp Immunol 1989; 77: 25-30.
20. Horikoshi T, Tamura J, Kanelo Y, et al. Membranous nephropathy associated with chronic thyroiditis. Nephron 1993; 63: 246.
21. Grcevska L, Polenalovic M, Petrus G. Membranous nephropathy associated with thyroid disorders. Nephron 2000; 86: 534-535.
22. Zhou MJ, Brown EJ. CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation. J Cell Biol 1994; 125: 1407-1416.
23. Edberg JC, Kimberly RP. Modulation of Fc gamma and complement receptor function by GPI-anchored form of Fc gamma RIII. J Immunol 1994; 152: 5826-5835.
24. Asayama K, Dobahsi K, Hayashibe H, Kato K. Vitamin E protects against thyroxine-induced acceleration of lipid peroxidation in cardiac and skeletal muscles in rats. J Nutr Sci Vitaminol 1989; 35: 407-418.
25. Venditti P, Balestrieri S, De Leo T. Effect of thyroid state on lipid peroxidation, antioxidant defences and susceptibility to oxidative stress in rat tissues. J Endocrinol 1997; 155: 151-157.
26. Sen CK, Parker L. Antioxidant and redox regulation of gene transcription. FASEB J 1996; 10: 709-720.
27. Seven A, Seymen O, Hatemi S, Hatemi H, Yigit G, Candan G. Antioxidant status in experimental hyperthyroidism: effect of vitamin E supplementation. Clin Chim Acta 1996; 256: 65-74.
28. Asayama K, Dabashi K, Hayashibe H, Megata Y, Kato K. Lipid peroxidation and the free radical scavengers in thyroid dysfunction in the rat: a possible mechanism of injury to heart and skeletal muscle in hyperthyroidism. Endocrinology 1987; 121: 2112-2118.
29. Magsino CH Jr, Hamouda W, Ghanim H, Brwne R, Aljada A, Dandona P. Effect of triiodotyronine on reactive oxygen species generation on leucocytes, indices of oxidative damage and oxidant reserve. Metabolism 2000; 49: 799-803.
30. Mano T, Shinorara R, Iwase K, et al. Changes in free radical scavengers and lipid peroxide in thyroid glands of various thyroid disorders. Horm Metab Res 1997; 29: 351-354.
31. Fernández V, Barrientos X, Kipreos K, Valenzuela A, Videla LA. Superoxide radical generation, NADPH oxidase acitivity, and cytocrome P-450 content of rat liver microsomal fractions in an experimental hyperthyroid state: relation to lipid peroxidation. Endocrinology 1985; 117: 496-501.
32. Mano T, Sinohora R, Sawai Y, et al. Effects of thyroid hormone on coenzyme Q and other free radical scavengers in rat heart muscle. J Endocrinol 1995; 145: 131-136.
33. Neradilová M, Hrubá F, Novakova V, Blahosová I. Investigations of the relationship between thyroid function and α-tocopherol concentration of serum and in some organs of rat. Int J Vit Nutr Res 1973; 43: 283-290.
34. Morini P, Casalin E, Sblano C, Landriscina C. The response of rat liver lipid peroxidation, antioxidant enzyme activities and glutathione concentration to the thyroid hormone. J Biochem 1991; 23: 1025-1030.
35. Wilson R, Choppra M, Bradley H, Mckillop JH, Smith WE. Free radicals and Graves' disease: the effect of therapy. Clin Endocrinol 1989; 30: 429-433.
36. Weetman AP, Holt ME, Campbell AK, Hall R, McGregor AM. Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression. Brit Med J 1984; 288(i): 518-520.
37. Komosinska-Vassev K, Olczyk K, Kucharz EJ, Marcisz C, Winz-Szczotka K, Kotulzka A. Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease during therapy. Clin Clin Acta 2000; 300: 107-117.
38. Bianchi G, Solaroli E, Zaccheroni V, Bargossi AM, Melchionda N, Marchesini G. Oxidative stress and antioxidant metabolites in patients with hyperthyroidism: effect of treatment. Horm Metab Res 1999; 31: 620-624.
39. Bartalena L. Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann Intern Med 1998; 129: 632-635.
40. Bouzas EA, Karadimas P, Mastorakos G, Koutras DA. Antioxidant agents in the treatment of Graves' opthalmopathy. Am J Ophthalmol 2000; 129: 618-622.
41. Guerra LN, Moiguer S, Karner M, Molina MDCR, Sreider CM, Burdman JA. Antioxidants in the treatment of Graves disease. IUBMB Life 2001; 51: 105-109.